Molecular Biology of Colon Cancer -- Chemoprevention of Colorectal Cancer -- Colorectal Cancer Screening and Surveillance -- Cytotoxic Chemotherapy for Metastatic Colorectal Cancer -- Integration of Antiangiogenic Strategies Into Colorectal Cancer Treatment -- The Role of EGFR Inhibition in Colorectal Cancer -- Second-Line Strategies in the Treatment of Patients With Metastatic Colorectal Cancer -- Adjuvant Chemotherapy for Colon Cancer -- Management of Locally Advanced Rectal Cancer -- Rationale for Adjuvant and Neoadjuvant Chemotherapy in the Resection of Liver Metastases -- Percutaneous Radiofrequency Ablation in the Management of Patients With Colorectal Cancer -- Colorectal Cancer Imaging -- Nursing Issues in Colorectal Cancer Chemotherapy -- Pain Management in the Colorectal Cancer Patient -- Novel Agents and New Paradigms for Colorectal Cancer Beyond EGFR and VEGF.

Management options for patients with colorectal cancer have undergone d- matic changes over the past decade. Whereas at the start of 1996 only one drug, 5-Fluorouracil, was available for the treatment of this disease, a mere 10 yr later, six drugs are licensed for use in colorectal cancer, and others are in the late phases of clinical development. Likewise, surgical and ablative options, as well as an array of supportive medications, have shown substantial progress and undergone a dramatic proliferation over the past decade. With the increased number of therapeutic options from which to choose, the clinician is better able to offer effective therapy to the patient with colorectal cancer. The clinician is challenged, however, to keep up with the rapidly changing landscape and the rapidly emerging data that shape the options for treatment today and tom- row. In this text, leaders in the management of colorectal cancer review the current literature that has led us to where we are today. Critical evaluations of the data are offered, and evidence-based recommendations are made.